The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
C-reactive protein (CRP) as a prognostic biomarker in patients with bladder cancer: A meta-analysis.
 
Yu Fujiwara
No Relationships to Disclose
 
Alexander B. Karol
No Relationships to Disclose
 
Emma Reford
No Relationships to Disclose
 
Himanshu Joshi
No Relationships to Disclose
 
Deborah Blythe Doroshow
Consulting or Advisory Role - AstraZeneca; Atheneum; Dedham Group; GlobalData; Mirati Therapeutics; MJH Life Sciences
Travel, Accommodations, Expenses - MJH Life Sciences
Other Relationship - Bristol Myers Squibb Foundation; Conquer Cancer Foundation
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792